Trials / Unknown
UnknownNCT02327676
Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Asian-Pacific Alliance of Liver Disease, Beijing · Academic / Other
- Sex
- All
- Age
- 2 Years – 17 Years
- Healthy volunteers
- Accepted
Summary
This study evaluates generic emtricitabine(FTC) in Chinese naive children chronic hepatitis B patients. Single group of child patients were enrolled, which include HBeAg positive and negative Chronic hepatitis B(CHB)group.
Detailed description
Generic emtricitabine(FTC) has been approved for treatment of naive chronic hepatitis B(CHB) patients in China. Yet data are limited for this agent in children paitients. The investigators design this trial to test the effect of FTC in Chinese children CHB which including naive HBeAg positive and Negative CHB patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Emtricitabine | emtricitabine were given to each patients for 48 weeks |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2015-07-01
- Completion
- 2016-07-01
- First posted
- 2014-12-30
- Last updated
- 2014-12-30
Source: ClinicalTrials.gov record NCT02327676. Inclusion in this directory is not an endorsement.